Abstract
Background Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known. Objective To evaluate the role of combination IV + SC enoxaparin in primary PCI in STEMI. Methods 83 consecutive patients with STEMI who underwent primary PCI between January 1, 2005 and January 15, 2008 were included. Anticoagulation was based on our institution’s STEMI protocol; either IV + SC enoxaparin, or IV unfractionated heparin (UFH). Clinical endpoints included MACE, bleeding and net adverse cardiac events (NACE). Results 45 patients received UFH and 37 received IV + SC enoxaparin. There was no difference in the rate of mortality, MACE, or NACE. There was a trend toward more TIMI major and GUSTO moderate and severe bleeding in the UFH group. Conclusions Application of IV + SC enoxaparin strategy for primary PCI in STEMI appears both safe and efficacious. A prospective randomized trial will be necessary to evaluate the safety and efficacy more thoroughly.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- PCI:
-
Percutaneous coronary intervention
- STEMI:
-
ST segment elevation myocardial infarction
- NSTEMI:
-
Non-ST segment elevation myocardial infarction
- UFH:
-
Unfractionated heparin
References
Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 117(2):296–329. doi:10.1161/CIRCULATIONAHA.107.188209
Van de Werf F, Ardissino D, Betriu A et al (2003) Task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 24(1):28–66. doi:10.1016/S0195-668X(02)00618-8
Murphy SA, Gibson CM, Morrow DA et al (2007) Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28(17):2077–2086. doi:10.1093/eurheartj/ehm224
Antman EM, Morrow DA, McCabe CH et al (2006) ExTRACT-TIMI 25 investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488. doi:10.1056/NEJMoa060898
Antman EM, Morrow DA, McCabe CH et al (2005) Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149:217–226
Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102(17):2031–2037
Califf RM, Phillips HR 3rd, Hindman MC et al (1985) Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5:1055
Bovill EG, Terrin ML, Stump DC et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 115(4):256–265
The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682. doi:10.1056/NEJM199309023291001
Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470
Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54. doi:10.1001/jama.292.1.45
Gibson CM, Murphy SA, Montalescot G et al (2007) Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2238–2246. doi:10.1016/j.jacc.2007.01.093
Buller CE, Pate GE, Armstrong PW et al (2006) Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 22:511–515
Welsh RC, Gordon P, Westerhout CM et al (2007) A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 70(3):341–348. doi:10.1002/ccd.21062
Montalescot G, White HD, Gallo R et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355:1006–1017. doi:10.1056/NEJMoa052711
Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295(13):1519–1530. doi:10.1001/jama.295.13.joc60038
Stone GW, Witzenbichler B, Guagliumi G, HORIZONS-AMI Trial Investigators et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358(21):2218–2230. doi:10.1056/NEJMoa0708191
Acknowledgement
The authors thank David Baran, MD, FACC, Monica Feinberg, RN.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khoobiar, S., Mejevoi, N., Kaid, K. et al. Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. J Thromb Thrombolysis 26, 85–90 (2008). https://doi.org/10.1007/s11239-008-0258-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-008-0258-2